Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

790

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Mosunetuzumab
DRUG: Lenalidomide
DRUG: Rituximab
DRUG: Obinutuzumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristin
DRUG: Prednisone
DRUG: Rituximab
DRUG: Obinutuzumab
DRUG: Bendamustin

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]
[object Object]
[object Object]